

CorriX™

The Next Generation Nutraceutical

Designed by nature, developed by science


A future generation of evidence-based nutraceuticals that will help to manage health and well-being from the inside out

The gut microbiome is a main contributor to human health and is essentially involved in the development and function of the immune system. Remarkably, gut bacteria are able to induce the development of antibodies against antigens present on their surface. Such antibodies are involved in key function of our immune system.

Humans have natural TF α -antibodies (Thomsen-Friedenreich antibodies), which are induced by gut bacteria carrying the TF α -antigen. These natural TF α -antibodies are important for immune health*.

The TF α -antibody level may be affected by modulation of the gut flora, e.g. due to changing habits.

Consequently, a regular dietary supplementation with a bacterium carrying the TF α -antigen can support the natural TF α -antibody level*.



CorriX™ provides a solution at highest quality and safety

Novel pasteurized gut bacterium

CorriX™ is composed of the heat-treated gut bacterium *Bacteroides xylanisolvens* carrying the TF α -antigen on its surface.

FDA GRAS and EFSA Novel Food authorized

CorriX™ is patented, FDA GRAS (Generally Recognized As Safe) and EFSA authorized as Novel Food. Safe for daily human consumption CorriX™ is developed as a natural food, beverage and supplement ingredient.



Unique effect

CorriX™ is the first evidence-based nutraceutical to support the physiologic development of specific natural TF α -antibodies involved in our immune health*.

Highest scientific standards

Developed in by now 10 years from lab to market, CorriX™ is backed with scientific research published in international peer-reviewed journals including a double-blind, randomized, placebo-controlled human study.

CorriX™ applications

- Food, beverage and supplement ingredient
- Pasteurized without losing efficacy (easy handling, transport and storage as well as maximum safety)
- For everyday use year round, safe and effective for daily consumption
- Marketing dosages (given in cells per day) analyzed in a human trial
- Kosher



Research

Human efficacy study

A randomized, double-blind, placebo controlled trial demonstrated that CorriX™ induces the development of natural TFα-IgM antibodies in humans [2]

Animal efficacy study

TFα-antigen-expressing Bacteroides induced the development of natural TFα-antibodies in mice [1]

Safety

The CorriX™-strain Bacteroides xylanisolvens is safe for human consumption [3-5]

Discovery


The CorriX™-strain Bacteroides xylanisolvens was isolated from a healthy human gut and is a new Bacteroides xylanisolvens strain.[4]

Human efficacy study: CorriX™ increases the TFα-antibody level in humans [2]


A double-blind, placebo-controlled study involving 140 healthy volunteers revealed that the oral uptake of pasteurized Bacteroides xylanisolvens (CorriX™) was able to increase the level of TFα-specific IgM antibodies:

Up to 50% and 75% of volunteers presented a significant increase in the TFα-specific IgM antibody level after 3 and 6 weeks of intake, respectively. The effect was dose-dependent, physiological and reverted after stopping the intake.

Proportion (%) of volunteers with increased relative TFα-antibody level (TFαR)



Mean increase in TFαR in group with CorriX™ (1x 10¹² cells/day) vs. placebo group



Reference List

1. Ulsemer P, Henderson G, Toutounian K, Loffler A, Schmidt J, Karsten U, Blaut M, Goletz S. Specific humoral immune response to the Thomsen-Friedenreich tumor antigen (CD176) in mice after vaccination with the commensal bacterium Bacteroides ovatus D-6. *Cancer Immunol.Immunother.* 2013;62:875-887
2. Ulsemer P, Toutounian K, Kressel G, Goletz C, Schmidt J, Karsten U, Hahn A, Goletz S. Impact of oral consumption of heat-treated Bacteroides xylanisolvens DSM 23964 on the level of natural TFα-specific antibodies in human adults. *Benef. Microbes.* 2016; 1-16
3. Ulsemer P, Toutounian K, Kressel G, Schmidt J, Karsten U, Hahn A, Goletz S. Safety and tolerance of Bacteroides xylanisolvens DSM 23964 in healthy adults. *Benef.Microbes.* 2012;3:99-111
4. Ulsemer P, Toutounian K, Schmidt J, Karsten U, Goletz S. Preliminary safety evaluation of a new Bacteroides xylanisolvens isolate. *Appl.Environ.Microbiol.* 2012; 78:528-535
5. Ulsemer P, Toutounian K, Schmidt J, Leuschner J, Karsten U, Goletz S. Safety assessment of the commensal strain Bacteroides xylanisolvens DSM 23964. *Regul.Toxicol.Pharmacol.* 2012; 62:336-346

Contact us: Avitop GmbH

Robert-Rössle-Str. 10
13125 Berlin, Germany
info@avitop.de
phone: +49 (0) 30 9489 2660
www.avitop-health.com

This document contains science, research, and technical documents meant only for product manufacturers and related professionals.

* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This statement has not been reviewed by food authorities (FDA, EFSA).